Thomas Woiwode - Net Worth and Insider Trading
Thomas Woiwode Net Worth
The estimated net worth of Thomas Woiwode is at least $172 Million dollars as of 2024-05-01. Thomas Woiwode is the Director of Audentes Therapeutics Inc and owns about 1,806,832 shares of Audentes Therapeutics Inc (BOLD) stock worth over $108 Million. Thomas Woiwode is the Director of CRISPR Therapeutics AG and owns about 645,643 shares of CRISPR Therapeutics AG (CRSP) stock worth over $35 Million. Thomas Woiwode is also the Director, 10% Owner of Tempest Therapeutics Inc and owns about 4,295,055 shares of Tempest Therapeutics Inc (TPST) stock worth over $16 Million. Besides these, Thomas Woiwode also holds Passage Bio Inc (PASG) , Gritstone Bio Inc (GRTS) , Aligos Therapeutics Inc (ALGS) . Details can be seen in Thomas Woiwode's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Thomas Woiwode has not made any transactions after 2022-04-29 and currently still holds the listed stock(s).
Transaction Summary of Thomas Woiwode
Thomas Woiwode Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas Woiwode owns 7 companies in total, including Aligos Therapeutics Inc (ALGS) , Adverum Biotechnologies Inc (ADVM) , and Gritstone Bio Inc (GRTS) among others .
Click here to see the complete history of Thomas Woiwode’s form 4 insider trades.
Insider Ownership Summary of Thomas Woiwode
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ALGS | Aligos Therapeutics Inc | 2021-04-26 | director |
| ADVM | Adverum Biotechnologies Inc | 2020-12-14 | director |
| GRTS | Gritstone Bio Inc | 2020-12-30 | director |
 | | 2020-03-03 | director & 10 percent owner |
| | 2018-05-15 | director |
| | 2016-08-24 | director |
| | 2022-04-29 | director & 10 percent owner |
Thomas Woiwode Latest Holdings Summary
Thomas Woiwode currently owns a total of 6 stocks. Among these stocks, Thomas Woiwode owns 1,806,832 shares of Audentes Therapeutics Inc (BOLD) as of July 25, 2016, with a value of $108 Million and a weighting of 63.08%. Thomas Woiwode owns 645,643 shares of CRISPR Therapeutics AG (CRSP) as of May 15, 2018, with a value of $35 Million and a weighting of 20.23%. Thomas Woiwode also owns 4,295,055 shares of Tempest Therapeutics Inc (TPST) as of April 29, 2022, with a value of $16 Million and a weighting of 9.05%. The other 3 stocks Passage Bio Inc (PASG) , Gritstone Bio Inc (GRTS) , Aligos Therapeutics Inc (ALGS) have a combined weighting of 7.64% among all his current holdings.
Latest Holdings of Thomas Woiwode
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BOLD | Audentes Therapeutics Inc | 2016-07-25 | 1,806,832 | 59.97 | 108,355,715 |
| CRSP | CRISPR Therapeutics AG | 2018-05-15 | 645,643 | 53.81 | 34,742,050 |
| TPST | Tempest Therapeutics Inc | 2022-04-29 | 4,295,055 | 3.62 | 15,548,099 |
| PASG | Passage Bio Inc | 2020-03-03 | 4,959,769 | 1.35 | 6,695,688 |
| GRTS | Gritstone Bio Inc | 2020-12-30 | 4,450,638 | 0.87 | 3,888,522 |
| ALGS | Aligos Therapeutics Inc | 2020-10-20 | 3,292,339 | 0.77 | 2,535,101 |
Holding Weightings of Thomas Woiwode
Thomas Woiwode Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas Woiwode has made a total of 0 transactions in Audentes Therapeutics Inc (BOLD) over the past 5 years. The most-recent trade in Audentes Therapeutics Inc is the acquisition of 35,000 shares on July 25, 2016, which cost Thomas Woiwode around $525,000.
According to the SEC Form 4 filings, Thomas Woiwode has made a total of 0 transactions in CRISPR Therapeutics AG (CRSP) over the past 5 years. The most-recent trade in CRISPR Therapeutics AG is the sale of 44,000 shares on May 15, 2018, which brought Thomas Woiwode around $3 Million.
According to the SEC Form 4 filings, Thomas Woiwode has made a total of 1 transactions in Tempest Therapeutics Inc (TPST) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Tempest Therapeutics Inc is the acquisition of 2,118,644 shares on April 29, 2022, which cost Thomas Woiwode around $5 Million.
More details on Thomas Woiwode's insider transactions can be found in the Insider Trading History of Thomas Woiwode table.Insider Trading History of Thomas Woiwode
- 1
Thomas Woiwode Trading Performance
GuruFocus tracks the stock performance after each of Thomas Woiwode's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas Woiwode is 51.65%. GuruFocus also compares Thomas Woiwode's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas Woiwode within 3 months outperforms 5 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Thomas Woiwode's insider trading performs compared to the benchmark.
Performance of Thomas Woiwode
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 63.64 | | | | | |
| Relative Return to S&P 500(%) | 65.47 | | | | | |
Thomas Woiwode Ownership Network
Thomas Woiwode Owned Company Details
What does Aligos Therapeutics Inc do?
Who are the key executives at Aligos Therapeutics Inc?
Thomas Woiwode is the director of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .
Aligos Therapeutics Inc (ALGS) Insider Trades Summary
Over the past 18 months, Thomas Woiwode made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,
In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 7,933,601 shares were bought by its insiders, resulting in a net purchase of 7,933,601 shares.
Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aligos Therapeutics Inc Insider Transactions
Thomas Woiwode Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas Woiwode. You might contact Thomas Woiwode via mailing address: One Sansome Street, Suite 1650, San Francisco Ca 94104.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
